ECSP21060868A - 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión - Google Patents

5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión

Info

Publication number
ECSP21060868A
ECSP21060868A ECSENADI202160868A ECDI202160868A ECSP21060868A EC SP21060868 A ECSP21060868 A EC SP21060868A EC SENADI202160868 A ECSENADI202160868 A EC SENADI202160868A EC DI202160868 A ECDI202160868 A EC DI202160868A EC SP21060868 A ECSP21060868 A EC SP21060868A
Authority
EC
Ecuador
Prior art keywords
disorder
dimethyltryptamine
dmt
meo
depression
Prior art date
Application number
ECSENADI202160868A
Other languages
English (en)
Inventor
Theis Terwey
Original Assignee
Gh Res Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65529503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21060868(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gh Res Ireland Limited filed Critical Gh Res Ireland Limited
Publication of ECSP21060868A publication Critical patent/ECSP21060868A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan composiciones para su uso en el tratamiento de un paciente que padece un trastorno mental en particular trastorno depresivo mayor, trastorno depresivo persistente, trastorno de ansiedad, trastorno de estrés postraumático, trastorno dismórfico corporal, trastorno obsesivo compulsivo, trastorno alimentario y abuso de sustancias psicoactivas. Se proporcionan además regímenes de dosificación para tratar estos trastornos.
ECSENADI202160868A 2019-02-22 2021-08-17 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión ECSP21060868A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19158774 2019-02-22

Publications (1)

Publication Number Publication Date
ECSP21060868A true ECSP21060868A (es) 2021-11-30

Family

ID=65529503

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202160868A ECSP21060868A (es) 2019-02-22 2021-08-17 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión

Country Status (32)

Country Link
US (2) US20220071958A1 (es)
EP (3) EP4349407B1 (es)
JP (2) JP7598326B2 (es)
KR (1) KR20210154966A (es)
CN (1) CN114555078A (es)
AU (2) AU2020225410B2 (es)
BR (1) BR112021016153A2 (es)
CA (1) CA3130406A1 (es)
CL (1) CL2021002174A1 (es)
CO (1) CO2021010882A2 (es)
CR (1) CR20210437A (es)
DK (2) DK3927337T3 (es)
DO (1) DOP2021000176A (es)
EA (1) EA202192318A1 (es)
EC (1) ECSP21060868A (es)
ES (2) ES2984438T3 (es)
FI (2) FI3927337T3 (es)
HR (2) HRP20250590T1 (es)
HU (2) HUE066828T2 (es)
IL (1) IL285537A (es)
LT (2) LT3927337T (es)
MA (1) MA55021B1 (es)
MD (1) MD3927337T2 (es)
MX (2) MX2021009941A (es)
NI (1) NI202100080A (es)
PE (1) PE20220015A1 (es)
PL (2) PL4349407T3 (es)
PT (2) PT4349407T (es)
RS (2) RS65706B1 (es)
SI (2) SI4349407T1 (es)
SM (1) SMT202400154T1 (es)
WO (1) WO2020169850A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4349407T1 (sl) 2019-02-22 2025-06-30 GH Research Ireland Limited 5-metoksi-n,n-dimetiltriptamin (5-meo-dmt) za zdravljenje velike depresivne motnje
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP3753923A1 (en) * 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
NZ788543A (en) 2019-11-07 2022-10-28 Small Pharma Ltd Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy
EP3868364A1 (en) 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
US11759452B2 (en) 2020-05-08 2023-09-19 Psilera Inc. Compositions of matter and pharmaceutical compositions
JP7766623B2 (ja) 2020-05-19 2025-11-10 サイビン アイアールエル リミテッド 重水素化トリプタミン誘導体および使用方法
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
WO2021250435A1 (en) 2020-06-12 2021-12-16 Beckley Psytech Limited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
CN116056705A (zh) * 2020-08-05 2023-05-02 巴塞尔大学医院 用于dmt辅助心理疗法的静脉内dmt施用方法
KR20230053611A (ko) 2020-08-18 2023-04-21 사이빈 아이알엘 리미티드 펜에틸아민 유도체, 조성물, 및 사용 방법
AU2021334933B2 (en) * 2020-08-28 2023-01-19 Cybin Uk Ltd Injectable formulation
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US20230355583A1 (en) * 2020-10-02 2023-11-09 Cybin Irl Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
CN112138028A (zh) * 2020-10-10 2020-12-29 南京中医药大学 蟾蜍色胺类物质在制备抗抑郁药物中的应用
WO2022082058A1 (en) * 2020-10-16 2022-04-21 Eleusis Therapeutics Us, Inc. Method of treatment by tryptamine alkaloids
EP4255421A1 (en) * 2020-12-01 2023-10-11 Small Pharma Ltd Inhalable formulations
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US20220265582A1 (en) * 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
CA3113414A1 (en) * 2021-03-29 2022-09-29 Mind Cure Health Inc. Psychedelics protocol computer systems and methods
US20230136824A1 (en) 2021-04-26 2023-05-04 ATAI Life Sciences AG N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
CN117320711A (zh) 2021-04-26 2023-12-29 阿泰治疗公司 新型n,n-二甲基色胺组合物和方法
EP4329759A4 (en) 2021-04-30 2025-07-16 Mind Medicine Inc CRYSTALLINE FORMS OF LSD SALTS
IL308068A (en) * 2021-05-03 2023-12-01 Mind Medicine Inc A method for dose titration of psychedelics
US20240246911A1 (en) * 2021-05-05 2024-07-25 Gilgamesh Pharmaceuticals Novel tryptamines and methods of treating mood disorders
US12378194B2 (en) 2021-05-25 2025-08-05 Atai Therapeutics, Inc. N, n-dimethyltryptamine salts and crystalline salt forms
WO2022261383A1 (en) 2021-06-09 2022-12-15 ATAI Life Sciences AG Novel prodrugs and conjugates of dimethyltryptamine
EP4387624A4 (en) 2021-08-19 2025-07-30 Mind Medicine Inc Immediate Release Formulations of Diethylamide of D-Lysergic Acid for Therapeutical Applications
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159201A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
IL312859A (en) * 2021-11-18 2024-07-01 Cybin Uk Ltd Injectable and inhalable formulations
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
US12012381B2 (en) 2021-12-30 2024-06-18 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
KR20250005178A (ko) 2022-03-27 2025-01-09 지에이치 리서치 아일랜드 리미티드 수면 장애의 치료에 사용하기 위한 5-meo-dmt
WO2023186834A1 (en) 2022-03-27 2023-10-05 GH Research Ireland Limited Crystalline hydrobromide salt of 5-meo-dmt
WO2023186816A1 (en) 2022-03-27 2023-10-05 GH Research Ireland Limited Treatment of anxiety
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
WO2024160391A1 (en) 2023-01-30 2024-08-08 GH Research Ireland Limited Treatment of mental disorders
EP4658265A1 (en) 2023-01-30 2025-12-10 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
GB202306256D0 (en) * 2023-04-27 2023-06-14 Beckley Psytech Ltd 5-Methoxy-N,N-Dimethyltryptamine Formulations
WO2024251807A1 (en) * 2023-06-08 2024-12-12 Cybin Irl Limited Companion animal treatments
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025068714A1 (en) * 2023-09-28 2025-04-03 Beckley Psytech Limited Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
AU2024367931A1 (en) 2023-10-23 2026-02-26 Reconnect Labs Ag Pharmaceutical formulations comprising 5-meo-dmt and their therapeutic uses
WO2025111597A1 (en) * 2023-11-22 2025-05-30 Gilgamesh Pharmaceuticals, Inc. A treatment for patients with mood disorders using n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine or a pharmaceutically acceptable salt thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20040127409A1 (en) 2002-11-07 2004-07-01 Milkhaus Laboratory, Inc. Method of treatment of psychological conditions by administration of nerve growth factor
ATE510174T1 (de) 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc Schlag gezündete unabhängige heizeinheit
EP1884254B8 (de) 2006-08-01 2011-02-23 Stobi GmbH & Co. KG Ventilballon für Inhalatoren
CN103816150A (zh) * 2014-03-14 2014-05-28 兰州理工大学 山蚂蝗生物碱单体成分的用途
US20200147038A1 (en) * 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
SI4349407T1 (sl) 2019-02-22 2025-06-30 GH Research Ireland Limited 5-metoksi-n,n-dimetiltriptamin (5-meo-dmt) za zdravljenje velike depresivne motnje

Also Published As

Publication number Publication date
EP4349407B1 (en) 2025-04-09
EP4353314A3 (en) 2024-07-03
JP2022521337A (ja) 2022-04-06
HUE066828T2 (hu) 2024-09-28
DK3927337T3 (da) 2024-04-22
EP4353314A2 (en) 2024-04-17
SI3927337T1 (sl) 2024-07-31
DK4349407T3 (da) 2025-05-26
MX2025002567A (es) 2025-04-02
NI202100080A (es) 2021-12-06
US20220071958A1 (en) 2022-03-10
SMT202400154T1 (it) 2024-07-09
SI4349407T1 (sl) 2025-06-30
PL4349407T3 (pl) 2025-07-21
EP3927337B1 (en) 2024-02-14
PL3927337T3 (pl) 2024-07-29
KR20210154966A (ko) 2021-12-21
BR112021016153A2 (pt) 2021-10-05
EP4349407A3 (en) 2024-07-03
CR20210437A (es) 2021-11-02
RS65706B1 (sr) 2024-08-30
MX2021009941A (es) 2021-12-10
FI4349407T3 (fi) 2025-06-02
CO2021010882A2 (es) 2022-01-17
JP2025029035A (ja) 2025-03-05
JP7598326B2 (ja) 2024-12-11
HUE071841T2 (hu) 2025-09-28
CN114555078A (zh) 2022-05-27
FI3927337T3 (fi) 2024-05-08
MA55021A (fr) 2021-12-29
US20240307350A1 (en) 2024-09-19
EP4349407A2 (en) 2024-04-10
PT3927337T (pt) 2024-05-17
EP3927337A1 (en) 2021-12-29
LT4349407T (lt) 2025-07-10
HRP20240532T1 (hr) 2024-07-19
CL2021002174A1 (es) 2022-01-28
EA202192318A1 (ru) 2021-12-21
EP3927337B8 (en) 2024-03-20
WO2020169850A1 (en) 2020-08-27
AU2020225410A1 (en) 2021-08-19
IL285537A (en) 2021-09-30
HRP20250590T1 (hr) 2025-07-04
LT3927337T (lt) 2024-07-10
MD3927337T2 (ro) 2024-08-31
CA3130406A1 (en) 2020-08-27
PT4349407T (pt) 2025-06-04
RS66912B1 (sr) 2025-07-31
MA55021B1 (fr) 2024-05-31
DOP2021000176A (es) 2021-11-21
AU2020225410B2 (en) 2025-10-30
PE20220015A1 (es) 2022-01-11
AU2026200720A1 (en) 2026-02-19
ES2984438T3 (es) 2024-10-29
ES3031965T3 (en) 2025-07-14

Similar Documents

Publication Publication Date Title
DOP2021000176A (es) 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión
CO2021010883A2 (es) Composiciones que comprenden 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales
MX2025007468A (es) Composiciones y metodos para el manejo de trastornos
MX2020011786A (es) Oligomeros antisentido para tratamiento de afecciones y enfermedades.
NI201700137A (es) Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue
MX2019011606A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2019013893A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
CO2021008187A2 (es) Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
EA201990976A1 (ru) Новый способ профилактического лечения непроизвольной потери массы
CL2022001167A1 (es) Tratamiento de trastornos hepáticos
BR112018009476A2 (pt) regime de dosagem de plasminogênio para cicatrização de ferimentos
BR112018015483A2 (pt) formulações farmacêuticas sólidas estáveis que contêm 2-(2-nitro-4-trifluorometil-benzoil)-1,3 -ciclo-hexanodiona
AR116592A1 (es) Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
MX2022005375A (es) Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con neoplasias mieloproliferativas (nmp) con navitoclax.
MX2023006855A (es) Formas de dosificacion y usos terapeuticos de l-4-cloro quinurenina
BR112019000711A2 (pt) xibornol como um agente virucida para uso no tratamento profilático ou terapêutico de uma infecção causada por um ou mais vírus e composto farmacêutico virucida
CL2025001006A1 (es) Uso de enavogliflozina para tratar o prevenir nefropatía.
AR117329A1 (es) Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica
CR20220247A (es) Uso de reboxetina para tratar los trastornos del sistema nervioso
MX385150B (es) 3-beta-hidroxi-5-alfa-pregnan-20-ona para uso en tratamiento médico.
Xu et al. PS126. DAPK1 interaction with NMDA receptor NR2B subunit underlies the rapid antidepressant effect
EA201991866A1 (ru) Комбинированная терапия